In the past week, AVXL stock has gone up by 10.56%, with a monthly decline of -6.04% and a quarterly surge of 45.09%. The volatility ratio for the week is 8.53%, and the volatility levels for the last 30 days are 6.55% for Anavex Life Sciences Corporation. The simple moving average for the past 20 days is 1.62% for AVXL’s stock, with a 5.14% simple moving average for the past 200 days.
Is It Worth Investing in Anavex Life Sciences Corporation (NASDAQ: AVXL) Right Now?
The stock has a 36-month beta value of 0.63. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AVXL is 82.12M, and at present, short sellers hold a 23.61% of that float. On September 20, 2024, the average trading volume of AVXL was 1.06M shares.
AVXL) stock’s latest price update
Anavex Life Sciences Corporation (NASDAQ: AVXL)’s stock price has gone rise by 4.73 in comparison to its previous close of 5.50, however, the company has experienced a 10.56% increase in its stock price over the last five trading days. globenewswire.com reported 2024-09-03 that NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11, 2024 in New York City.
Analysts’ Opinion of AVXL
Many brokerage firms have already submitted their reports for AVXL stocks, with Cantor Fitzgerald repeating the rating for AVXL by listing it as a “Neutral.” The predicted price for AVXL in the upcoming period, according to Cantor Fitzgerald is $11 based on the research report published on December 06, 2022 of the previous year 2022.
Berenberg, on the other hand, stated in their research note that they expect to see AVXL reach a price target of $40. The rating they have provided for AVXL stocks is “Buy” according to the report published on June 23rd, 2022.
BTIG Research gave a rating of “Buy” to AVXL, setting the target price at $35 in the report published on September 23rd of the previous year.
AVXL Trading at -3.58% from the 50-Day Moving Average
After a stumble in the market that brought AVXL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.88% of loss for the given period.
Volatility was left at 6.55%, however, over the last 30 days, the volatility rate increased by 8.53%, as shares sank -9.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.68% upper at present.
During the last 5 trading sessions, AVXL rose by +10.56%, which changed the moving average for the period of 200-days by -23.91% in comparison to the 20-day moving average, which settled at $5.64. In addition, Anavex Life Sciences Corporation saw -38.13% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVXL starting from Donhauser Peter D.O., who purchase 2,835 shares at the price of $3.64 back on Jun 14 ’24. After this action, Donhauser Peter D.O. now owns 5,000 shares of Anavex Life Sciences Corporation, valued at $10,319 using the latest closing price.
Thomas Steffen, the Director of Anavex Life Sciences Corporation, purchase 5,000 shares at $4.52 during a trade that took place back on May 15 ’24, which means that Thomas Steffen is holding 5,000 shares at $22,600 based on the most recent closing price.
Stock Fundamentals for AVXL
The total capital return value is set at -0.37. Equity return is now at value -30.03, with -27.74 for asset returns.
Based on Anavex Life Sciences Corporation (AVXL), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 32.72. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is 140805.78.
Currently, EBITDA for the company is -47.5 million with net debt to EBITDA at 2.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.04.
Conclusion
To sum up, Anavex Life Sciences Corporation (AVXL) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
